Literature DB >> 17592100

Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease.

Judith I Tsui1, Eric Vittinghoff, Michael G Shlipak, Daniel Bertenthal, John Inadomi, Rudolph A Rodriguez, Ann M O'Hare.   

Abstract

BACKGROUND: Infection with chronic hepatitis C virus (HCV) has been linked to glomerulonephritis. We undertook this study to determine whether having a positive HCV test result was associated with an increased risk for developing treated end-stage renal disease (ESRD).
METHODS: Using data from Medicare, the Department of Veterans Affairs, and the United States Renal Data System, we performed a retrospective cohort study of 474,369 adult veterans who had serum creatinine levels measured between October 1, 2000, and September 30, 2001, and HCV antibody testing within 1 year of creatinine testing. Patients were followed up until October 1, 2004, for the outcome of treated ESRD, defined as the onset of chronic dialysis or renal transplantation. Cox proportional hazards models were used to determine the relative hazard for ESRD associated with HCV, adjusted for other covariates (age, sex, race/ethnicity, and comorbidities).
RESULTS: Of 474,369 patients in the cohort, 52,874 (11.1%) had a positive HCV antibody test result. Patients with HCV were more likely to develop ESRD: the rate per 1000 person-years was 4.26 (95% confidence interval, 3.97-4.57) for HCV-seropositive patients vs 3.05 (95% confidence interval, 2.96-3.14) for HCV-seronegative patients. For patients aged 18 to 70 years with an estimated glomerular filtration rate of at least 30 mL/min per 1.73 m2, HCV seropositivity was associated with a greater than 2-fold risk for developing ESRD (adjusted hazard rate, 2.80; 95% confidence interval, 2.43-3.23).
CONCLUSION: In this large national cohort of adult veterans, patients younger than 70 years with HCV seropositivity were at increased risk for developing ESRD treated with dialysis or transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592100     DOI: 10.1001/archinte.167.12.1271

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  65 in total

Review 1.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Mohammad A B Al-Freah; Zeino Zeino; Michael A Heneghan
Journal:  Curr Gastroenterol Rep       Date:  2012-02

2.  Prophylaxis of chronic kidney disease after liver transplantation--experience from west China.

Authors:  Zhen-Yong Shao; Lu-Nan Yan; Wen-Tao Wang; Bo Li; Tian-Fu Wen; Jia-Yin Yang; Ming-Qing Xu; Ji-Chun Zhao; Yong-Gang Wei
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 3.  Hepatitis C virus infection and kidney disease: a meta-analysis.

Authors:  Fabrizio Fabrizi; Paul Martin; Vivek Dixit; Piergiorgio Messa
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

4.  High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents.

Authors:  Ahmed Yahia Elmowafy; Hanzada Mohamed El Maghrabi; Mohamed Elsayed Mashaly; Khaled Farouk Eldahshan; Lionel Rostaing; Mohamed Adel Bakr
Journal:  Int Urol Nephrol       Date:  2019-10-14       Impact factor: 2.370

Review 5.  Gene-gene and gene-environment interactions in HIV-associated nephropathy: A focus on the MYH9 nephropathy susceptibility gene.

Authors:  Marina Núñez; Anita M Saran; Barry I Freedman
Journal:  Adv Chronic Kidney Dis       Date:  2010-01       Impact factor: 3.620

Review 6.  The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis.

Authors:  Christina M Wyatt; Carlos Malvestutto; Steven G Coca; Paul E Klotman; Chirag R Parikh
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177

7.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

8.  Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.

Authors:  Kazuki Ohya; Michio Imamura; Mitsutaka Osawa; Yuji Teraoka; Kei Morio; Hatsue Fujino; Atsushi Ono; Takashi Nakahara; Eisuke Murakami; Masami Yamauchi; Tomokazu Kawaoka; Akira Hiramatsu; Masataka Tsuge; Hiroshi Aikata; Clair Nelson Hayes; Kazuaki Chayama
Journal:  Clin J Gastroenterol       Date:  2019-08-28

9.  Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.

Authors:  Varun Saxena; Farrukh M Koraishy; Meghan E Sise; Joseph K Lim; Monica Schmidt; Raymond T Chung; Annmarie Liapakis; David R Nelson; Michael W Fried; Norah A Terrault
Journal:  Liver Int       Date:  2016-03-24       Impact factor: 5.828

10.  Authors' reply.

Authors:  S Jasuja; A K Gupta; R Choudhry; V Kher; D K Aggarwal; A Mishra; M Agarwal; A Sarin; M K Mishra; V Raina
Journal:  Indian J Nephrol       Date:  2009-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.